Syngene introduces a new platform for rapid protein synthesis
Syngene has introduced a novel protein synthesis platform that provides faster output while lowering risk
Syngene International, a contract research, development, and manufacturing organization (CRDMO), has introduced a novel protein production platform designed for quick production. The platform is built on cell line and transposon technologies licensed by Syngene from ExcellGene, a Swiss-based service provider that specializes in mammalian cell line generation. The new platform, when combined with Syngene's clone selection and development methods, provides a significant boost in efficiency and precision, according to a business press release issued on June 4, 2024.
"By merging ExcellGene's cell line and transposon-based platforms with our proprietary techniques, we are pushing the boundaries of cell line development. This novel approach will not only shorten development timelines but also improve the overall reliability and efficiency of the process, resulting in significant benefits for our clients," said Sridevi Khambhampaty, vice-president, Biopharmaceutical Development, Syngene International, in the press release.
"Syngene believes that biologics will be a crucial driver of future growth, and we are committed to investing in cutting-edge technology to provide clients with reliability, precision, and speed. By combining Syngene's skills and experience with ExcellGene's best-in-class cell line development technology, we can get molecules to market faster for the people and patients who need them," said Alex Del Priore, senior vice-president, Manufacturing Services, Syngene International, in a statement.
According to Syngene, the platform's adaptability allows for integration with perfusion and fed-batch manufacturing methods. "By combining this technology with Syngene's existing capabilities, the [c]ompany now offers a full range of end-to-end cell line development options, using the latest technology to deliver tangible benefits to customers," according to the announcement.
"High yield manufacturing is a multifactorial process that begins with transfections and an optimal cell host. We are obviously thrilled to collaborate with Syngene and contribute to its process development and manufacturing capabilities. This will use our technology and cells (CHOExpress) to benefit their large client base. ExcellGene takes pride in decades of research into the profound issues of DNA transfer to grown cells, linking findings to phenotypes and applications in manufacturing. "We are delighted that our work, combined with the talent and expertise of the Syngene team, will directly benefit patients around the world," said Maria J. and Florian M. Wurm, co-founders and managers of ExcellGene, in a statement.
Source: Syngene International
